Rivastigmine (Exelon), chemically known as (S)-N-ethyl-N-methyl-3-[(1-dimethylamino) ethyl]-phenyl carbamate hydrogen tartrate (RIV) is an acetylcholine esterase inhibitor of the carbamate type approved for the treatment of Alzheimer's disease [1], which is a progressive, degenerative brain disorder that affects reason, judgment and memory. Over a period, people with Alzheimer's disease lose their ability to think and reason clearly, judge situations, solve problems, concentrate, remember useful information, take care of themselves, and even speak [2] and [3]. People with mild Alzheimer's disease usually require close supervision and help with everyday tasks; and those with severe disease can do little on their own and require complete full-time care. Alzheimer's disease severely impacts the quality of life of the patient, their family and caregivers.